Browsing by Author "Pandey, Akhilesh"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Calcium calmodulin dependent kinase kinase 2-a novel therapeutic target for gastric adenocarcinoma
    (2015) Subbannayya, Yashwanth; Syed, Nazia; Barbhuiya, Mustafa A.; Roa Strauch, Juan Carlos Enrique; Marimuthu, Arivusudar; Sahasrabuddhe, Nandini; Pinto, Sneha M.; Manda, Srikanth Srinivas; Renuse, Santosh; Manju, HC; Zameer, Mohammed Abdul Lateef; Sharma, Jyoti; Brait, Mariana; Srikumar, Kotteazeth; Raja, Remya; Vijaya Kumar, M.; Kumar, KV Veerendra; Prasad, TS Keshava; Ramaswamy, Girija; Kumar, Rekha Vijay; Pandey, Akhilesh; Gowda, Harsha; Chatterjee, Aditi
  • No Thumbnail Available
    Item
    Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor
    (2023) Sawant, Mithila; Wilson, Audrey; Sridaran, Dhivya; Mahajan, Kiran; O'Conor, Christopher J.; Hagemann, Ian S.; Luo, Jingqin; Weimholt, Cody; Li, Tiandao; Roa, Juan Carlos; Pandey, Akhilesh; Wu, Xinyan; Mahajan, Nupam P.
    Hormone receptor-positive, HER2-negative advanced breast cancers exhibit high sensitivity to CDK4/6 inhibitors such as palbociclib. However, most patients inevitably develop resistance, thus identification of new actionable therapeutic targets to overcome the recurrent disease is an urgent need. Immunohistochemical studies of tissue microarray revealed increased activation of non-receptor tyrosine kinase, ACK1 (also known as TNK2) in most of the breast cancer subtypes, independent of their hormone receptor status. Chromatin immunoprecipitation studies demonstrated that the nuclear target of activated ACK1, pY88-H4 epigenetic marks, were deposited at cell cycle genes, CCNB1, CCNB2 and CDC20, which in turn initiated their efficient transcription. Pharmacological inhibition of ACK1 using its inhibitor, (R)-9b dampened CCNB1, CCNB2 and CDC20 expression, caused G2/M arrest, culminating in regression of palbociclib-resistant breast tumor growth. Further, (R)-9b suppressed expression of CXCR4 receptor, which resulted in significant impairment of metastasis of breast cancer cells to lung. Overall, our pre-clinical data identifies activated ACK1 as an oncogene that epigenetically controls the cell cycle genes governing the G2/M transition in breast cancer cells. ACK1 inhibitor, (R)-9b could be a novel therapeutic option for the breast cancer patients that have developed resistance to CDK4/6 inhibitors.
  • Thumbnail Image
    Item
    Quantitative phosphoproteomic analysis of IL-33-mediated signaling
    (2015) Pinto, Sneha M.; Sekhar Nirujogi, Raja; Leal Rojas, Pamela; Patil, Arun H.; Manda, Srikanth S.; Subbannayya, Yashwanth; Roa Strauch, Juan Carlos Enrique; Chatterjee, Aditi; Keshava Prasad, T. S.; Pandey, Akhilesh
  • Thumbnail Image
    Item
    Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
    (2017) Weber, Helga; Valbuena Mora, José Rafael; Barbhuiya, Mustafa A.; Stein, Stefan; Kunkel, Hana; García Muñoz, Patricia; Bizama, Carolina; Riquelme, Ismael; Espinoza, Jaime A.; Kurtz, Stephen E.; Tyner, Jeffrey W.; Calderon, Juan Francisco; Corvalán R., Alejandro; Grez, Manuel; Pandey, Akhilesh; Leal Rojas, Pamela; Roa Strauch, Juan Carlos Enrique